Lenalidomide Plus R-CHOP for CNS Relapse Prophylaxis in Diffuse Large B-cell Lymphoma
This is an open-label, multicenter, phase 2 trial to explore the efficacy and safety of the combination of lenalidomide and R-CHOP for preventing the CNS relapse in the high-risk diffuse large B cell lymphoma.
Diffuse Large B Cell Lymphoma
DRUG: Lenalidomide
The 2-year central nervous system relapse rates, The 2-year central nervous system relapse rates, two year
The 2-year overall survival, The 2-year overall survival, two year|The 2-year progression-free survival, The 2-year progression-free survival, two year|Incidence of treatment-emergent adverse events, Adverse events were classified as defined by the National Cancer Institute Common Toxicity Criteria, version 2. Safety evaluations were focused especially on neurological symptoms and the development of deep venous thrombosis (DVT)., two year
This is an open-label, multicenter, phase 2 trial to explore the efficacy and safety of the combination of lenalidomide and R-CHOP for preventing the CNS relapse in the high-risk diffuse large B cell lymphoma.